BioSpace News Archive

Drug Development

Fauci: Moderna COVID-19 Phase III Trial to Begin in July with 30,000 Patients

Of the Phase III trial, Fauci indicated that the majority of trial participants will be between the ages of 18 and 55, but will include elderly Americans that are most at risk of serious illness from COVID-19.

June 3, 2020
·
4 min read
·
Mark Terry
Business

Irish Biotech Company Shorla Raises $8.3 Million Series A

The round was led by Seroba Life Sciences, a European venture capital firm in Dublin.

June 3, 2020
·
2 min read
·
Mark Terry
BioSpace Global Roundup, June 4

Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.

June 3, 2020
·
6 min read
·
Alex Keown
Business

NodThera Secures $55 Million to Develop NLRP3 Inflammasome Inhibitors

U.K.-based NodThera is building up its war chest to develop therapies for diseases driven by chronic inflammation.

June 3, 2020
·
2 min read
·
Alex Keown
Business

When Will a COVID-19 Vaccine be Ready… and Why Then?

Industry experts say a vaccine against the SARS-CoV-2 virus will either be ready this fall, at the end of the year or 18 months from now, depending on the vaccine and how they define “ready.”

June 3, 2020
·
5 min read
·
Gail Dutton
Could ‘Turning Off’ a Key Gene Prevent the Development of Triple-Negative Breast Cancer?

On Tuesday, researchers from the Tulane University School of Medicine announced that they have identified a gene that causes an aggressive form of breast cancer to grow quickly. In addition, they have discovered a way to “turn off” this gene and prevent the cancer from occurring.

June 3, 2020
·
2 min read
Drug Development

LabCorp Launches Website to Connect Patients with COVID-19 Clinical Trials

The company announced its Covance drug development business was launching COVID-19 Clinical Trial Connect in the U.S. to help people find information on taking part in clinical trials related to COVID-19.

June 3, 2020
·
3 min read
·
Mark Terry
Drug Development

Imago BioSciences Advances Myelofibrosis Trials, With Phase IIb Prelim Readout Imminent

Imago BioSciences will announce preliminary results from its Phase IIb clinical trial for myelofibrosis (MF) at the 25th European Hematology Association (EHA) Annual Congress that begins June 12, 2020.

June 3, 2020
·
3 min read
·
Gail Dutton
Drug Development

Biopharma Update on the Novel Coronavirus: June 3

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 3, 2020.

June 3, 2020
·
4 min read
·
BioSpace Editorial Staff
FDA

FDA Delays Ruling on Novartis’ Relapsing Multiple Sclerosis Drug Arzerra

On Tuesday, the FDA extended its review of the Supplemental Biologics License Application for Arzerra in this indication by three months.

June 3, 2020
·
2 min read
·
Alex Keown